Exparel competition

[caligas]

Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain | BioSpace

Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain - read this article along with other careers information, tips and advice on BioSpace

www.biospace.com

---

Members don't see this ad.

 

[26B]

Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain | BioSpace

Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain - read this article along with other careers information, tips and advice on BioSpace

www.biospace.com

The literature already basically says Exparel offers no benefits over plain bupivacaine for peripheral nerve blocks. This new drug seems interesting in that they've at least compared it to plain bupivacaine in the trials, vs. Exparel which was compared against placebo (saline) once they realized there was no difference vs. plain bupi.

Edit: just realized that article you posted is 2 years old. A quick literature doesn't come up with much in the last 2 years.

Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia: A Systematic Review and Meta-analysis

Nine trials were included in a meta-analysis examining the difference in 24- to 72-h rest pain severity scores for liposomal and nonliposomal bupivacaine. The area under the curve pain scores for the 24- to 72-h period were statistically but probably not clinically significant. Secondary outcome...

pubs.asahq.org

 

[caligas]

The literature already basically says Exparel offers no benefits over plain bupivacaine for peripheral nerve blocks. This new drug seems interesting in that they've at least compared it to plain bupivacaine in the trials, vs. Exparel which was compared against placebo (saline) once they realized there was no difference vs. plain bupi.

Edit: just realized that article you posted is 2 years old. A quick literature doesn't come up with much in the last 2 years.

Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia: A Systematic Review and Meta-analysis

Nine trials were included in a meta-analysis examining the difference in 24- to 72-h rest pain severity scores for liposomal and nonliposomal bupivacaine. The area under the curve pain scores for the 24- to 72-h period were statistically but probably not clinically significant. Secondary outcome...

pubs.asahq.org

Sorry, meant to post the one from this year

HTX-011 yielded mild pain scores, reduced opioid use after bunionectomy

Published results showed HTX-011 may lead to mild postoperative pain scores and reduced opioid use after bunionectomy. In this follow-up to the EPOCH-1 study, 31 patients undergoing unilateral, distal bunionectomy of the first metatarsal with osteotomy and internal fixation received a...

www.healio.com